Combination treatments with therapeutic hypothermia for hypoxic-ischemic neuroprotection
Areas Without Adequate Human Evidence Long-term cardiovascular safety Long-term neurological safety Endocrine effects beyond selected hormone measurements Effects on glucose regulation in people Immune responses Allergic reactions Genotoxicity Carcinogenicity Effects in people with cancer or precancerous disease Reproductive and developmental toxicity Pregnancy safety Breastfeeding safety Paediatric exposure Medicine interactions Interaction with hormone or sleep treatments Repeated exposure over months or years Product-Quality Risks Incorrect amino-acid sequence Glu and Asp residue-order errors Wrong terminal groups Incorrect free-base or acetate designation Incorrect peptide quantity Deletion-sequence impurities Incomplete deprotection Residual synthesis reagents Residual solvents Peptide aggregates Degradation during transport or storage Unverified microbiological quality Unverified bacterial-endotoxin control Certificates unrelated to the supplied batch No reports does not mean no risk FDAs adverse-event database search found no Epitalon reports through December 2025
doi:10.3390/nu12123819 [49] Tebben PJ, Singh RJ, Kumar R
higher doses require split injections) 12 weeks: 1224 syringes 24 weeks: 2448 syringes Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution
Rahimi, R., Nikfar, S., Rezaie, A., and Abdollahi, M
To maintain balanced production of bioactive folate metabolites, interconversion occurs at both the mitochondrial and cytosolic levels
&srotate=0)
